Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

Alto Neuroscience (NYSE:ANRO) FY Conference September 09, 2025 02:00 PM ET Company ParticipantsAmit Etkin - CEOConference Call ParticipantsPatrick Trucchio - Biotechnology AnalystPatrick TrucchioGood afternoon, everyone. Welcome back to the H.C. Wainwright 27th Annual Global Investment Conference on September 8 to September 10, 2025. I'm Patrick Trucchio, a Senior Healthcare Analyst at HC Wainwright. It's my pleasure to introduce our next company, Alto Neuroscience, a clinical-stage biopharmaceutical compan ...

What to do next: To join the Alto class action, go to https://rosenlegal.com/submit-form/?case_id=42321 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified ...

"Company†) (NYSE: ANRO). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On October 22, 2024, Alto issued a press release annou. NEW YORK--(BUSINESS WIRE)---- $ANRO #ANRO--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto†or the ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #biomarkers--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced positive results from an independent, prospective replication study evaluating electroencephalography (EEG) biomarkers in people with schizophrenia. The study successfully replicated previous findings, demonstrating that event-related theta-band responses ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Alto [4]. - Investors who purchased Alto stock during the class period from February 2, 2024, to October 22, 2024, are encouraged to discuss their legal rights [1][4]. - The complaint alleges that Alto and its executives made false statements regarding ALTO-100's effectiveness, overstating its clinical and commercial prospects [6]. Group 2: Stock Performance and Market Reaction - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share [7]. - Analysts reacted swiftly, with Jeffries reducing its price target for Alto from $33 to $17, citing concerns about the company's biomarker approach to CNS disorders [8]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [2][4]. Group 1: Legal Investigation - The firm is reminding investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Alto [2]. - The complaint alleges that Alto and its executives violated federal securities laws by making false statements about ALTO-100's effectiveness and overstating the company's business prospects [4][5]. Group 2: Financial Impact - Following the announcement that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [5]. - Analysts reacted by cutting their price target for Alto from $33 to $17, raising concerns about the company's overall approach to CNS disorders and psychiatry [6]. Group 3: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [7]. - Faruqi & Faruqi encourages anyone with information regarding Alto's conduct to contact the firm, including whistleblowers and former employees [7].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, leading to overstated clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that during the class period, Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against Alto Neuroscience - The lawsuit claims that Alto misrepresented the effectiveness of ALTO-100 in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [5]. - As a result of these misrepresentations, Alto's business and financial prospects were also overstated, leading to investor damages when the truth was revealed [5].